tolterodine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2705	124937-51-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tolterodine tolterodine tartrate (+)-Tolterodine (R)-Tolterodine	An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE. Molecular weight: 325.50 Formula: C22H31NO CLOGP: 5.24 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.78 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tolterodine
tolterodine tartrate
(+)-Tolterodine
(R)-Tolterodine

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

Molecular weight: 325.50
Formula: C22H31NO
CLOGP: 5.24
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.78
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	12 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 25, 1998	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	112.04	11.79	280	22737	240233	56028817
Sensitivity to weather change	98.36	11.79	50	22967	6599	56262451
Urinary incontinence	96.87	11.79	87	22930	29498	56239552
Multiple sclerosis	83.69	11.79	78	22939	27724	56241326
Multiple sclerosis relapse	82.95	11.79	97	22920	44806	56224244
Dry mouth	79.82	11.79	114	22903	64091	56204959
Fall	72.87	11.79	314	22703	357196	55911854
Pollakiuria	72.58	11.79	69	22948	25133	56243917
Hypertonic bladder	65.01	11.79	30	22987	3202	56265848
Maternal exposure during pregnancy	58.92	11.79	5	23012	189548	56079502
Contraindicated product administered	55.03	11.79	6	23011	186280	56082770
Bladder disorder	53.54	11.79	36	22981	7988	56261062
Nocturia	47.70	11.79	32	22985	7074	56261976
Antinuclear antibody negative	47.03	11.79	12	23005	204	56268846
Treatment failure	46.67	11.79	7	23010	170385	56098665
Coombs positive haemolytic anaemia	45.99	11.79	13	23004	331	56268719
Off label use	40.82	11.79	106	22911	556074	55712976
Glossodynia	37.98	11.79	8	23009	152450	56116600
Drug intolerance	37.40	11.79	32	22985	264786	56004264
Herpes simplex reactivation	37.08	11.79	12	23005	488	56268562
Cerebrovascular accident	35.48	11.79	105	22912	99165	56169885
Infusion related reaction	35.05	11.79	21	22996	208910	56060140
Systemic lupus erythematosus	34.84	11.79	15	23002	180063	56088987
Exposure during pregnancy	34.28	11.79	7	23010	136335	56132715
Hallucination, auditory	34.03	11.79	32	22985	11492	56257558
Paranoia	33.98	11.79	31	22986	10713	56258337
Stress urinary incontinence	31.25	11.79	16	23001	2142	56266908
Wound	31.23	11.79	9	23008	138795	56130255
Micturition urgency	31.08	11.79	27	22990	8754	56260296
Rheumatoid arthritis	30.31	11.79	70	22947	382534	55886516
Bladder spasm	29.89	11.79	14	23003	1545	56267505
Depression	29.77	11.79	149	22868	179968	56089082
Urinary retention	29.36	11.79	46	22971	28028	56241022
Balance disorder	29.32	11.79	83	22934	76437	56192613
Gastritis haemorrhagic	28.01	11.79	13	23004	1406	56267644
Dizziness	27.96	11.79	255	22762	375885	55893165
Transient ischaemic attack	27.10	11.79	49	22968	33528	56235522
Hyperlipidaemia	26.79	11.79	35	22982	18074	56250976
Antiphospholipid syndrome	26.36	11.79	13	23004	1608	56267442
Coronary artery disease	26.21	11.79	46	22971	30750	56238300
Abdominal discomfort	25.98	11.79	46	22971	277228	55991822
Gastrooesophageal reflux disease	25.97	11.79	84	22933	83173	56185877
Complex regional pain syndrome	23.06	11.79	13	23004	2110	56266940
Oesophagitis	22.09	11.79	28	22989	14029	56255021
Swelling	21.37	11.79	41	22976	239730	56029320
Pericarditis	21.17	11.79	9	23008	108914	56160136
Incontinence	21.17	11.79	24	22993	10711	56258339
Hepatic enzyme increased	20.41	11.79	24	22993	171360	56097690
Gait disturbance	20.22	11.79	125	22892	163196	56105854
Mental status changes	19.89	11.79	46	22971	37455	56231595
Hypothyroidism	19.33	11.79	46	22971	38150	56230900
Infection	18.93	11.79	33	22984	200173	56068877
Anxiety disorder	18.27	11.79	14	23003	3806	56265244
Pain	18.01	11.79	179	22838	663005	55606045
Myocardial infarction	17.62	11.79	80	22937	92790	56176260
Urge incontinence	17.45	11.79	8	23009	841	56268209
Product use issue	17.29	11.79	31	22986	186010	56083040
White blood cell count abnormal	16.76	11.79	16	23001	5851	56263199
Iliac artery occlusion	16.66	11.79	5	23012	158	56268892
Constipation	16.56	11.79	140	22877	201803	56067247
Stomatitis	16.55	11.79	15	23002	120795	56148255
Barrett's oesophagus	16.54	11.79	7	23010	608	56268442
Secondary progressive multiple sclerosis	16.52	11.79	9	23008	1366	56267684
Osteonecrosis	16.39	11.79	32	22985	23183	56245867
Liver iron concentration abnormal	16.27	11.79	4	23013	58	56268992
Toxicity to various agents	16.25	11.79	43	22974	224521	56044529
Peritonitis	16.18	11.79	26	22991	16176	56252874
Drug abuse	15.92	11.79	4	23013	67606	56201444
Dysphagia	15.85	11.79	71	22946	81876	56187174
Aphonia	15.83	11.79	19	22998	9010	56260040
Completed suicide	15.65	11.79	19	22998	133814	56135236
Neutrophil count abnormal	15.51	11.79	11	23006	2659	56266391
Cardiac failure congestive	15.49	11.79	74	22943	87646	56181404
Body temperature fluctuation	15.45	11.79	10	23007	2082	56266968
Drug hypersensitivity	15.34	11.79	176	22841	275029	55994021
Mixed incontinence	14.97	11.79	4	23013	82	56268968
Confusional state	14.85	11.79	140	22877	208015	56061035
Product complaint	14.77	11.79	21	22996	11739	56257311
Malignant neoplasm progression	14.43	11.79	6	23011	73581	56195469
Varicose ulceration	14.34	11.79	6	23011	506	56268544
Neurogenic bladder	14.26	11.79	11	23006	3018	56266032
Colitis ischaemic	14.25	11.79	19	22998	10001	56259049
Haemoglobin abnormal	14.01	11.79	13	23004	4591	56264459
Discomfort	13.73	11.79	23	22994	141738	56127312
Arthropathy	13.27	11.79	40	22977	200235	56068815
Neutropenia	13.26	11.79	28	22989	158139	56110911
Blister	13.22	11.79	15	23002	108872	56160178
Increased appetite	13.10	11.79	17	23000	8718	56260332
Perforation	13.00	11.79	7	23010	1039	56268011
Escherichia urinary tract infection	12.91	11.79	19	22998	10956	56258094
Chronic obstructive pulmonary disease	12.85	11.79	52	22965	57363	56211687
Irritable bowel syndrome	12.76	11.79	6	23011	68452	56200598
Visual impairment	12.67	11.79	62	22955	74140	56194910
Psychotic disorder	12.60	11.79	29	22988	23529	56245521
Skin disorder	12.58	11.79	31	22986	26278	56242772
Pathological fracture	12.53	11.79	16	23001	8073	56260977
Therapy non-responder	12.50	11.79	54	22963	61301	56207749
Febrile neutropenia	12.32	11.79	15	23002	105530	56163520
Cystitis	12.26	11.79	46	22971	48992	56220058
Haemoglobin	12.12	11.79	4	23013	173	56268877
Blood triglycerides increased	12.02	11.79	19	22998	11658	56257392

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seronegative arthritis	66.08	15.20	19	7080	957	31689288
Lipoma	57.50	15.20	19	7080	1524	31688721
Pollakiuria	51.55	15.20	38	7061	17864	31672381
Dry mouth	51.18	15.20	43	7056	24415	31665830
Fall	46.90	15.20	118	6981	185971	31504274
Urinary incontinence	45.94	15.20	35	7064	17285	31672960
Prostatic specific antigen increased	41.84	15.20	30	7069	13508	31676737
Urinary retention	39.43	15.20	43	7056	33682	31656563
Inflammatory marker increased	39.17	15.20	19	7080	4159	31686086
Balance disorder	39.11	15.20	45	7054	37377	31652868
Musculoskeletal discomfort	32.45	15.20	20	7079	7003	31683242
Micturition urgency	30.75	15.20	18	7081	5742	31684503
Multiple sclerosis	29.98	15.20	20	7079	8017	31682228
Urinary tract infection	22.78	15.20	52	7047	76817	31613428
Confusional state	21.35	15.20	72	7027	133262	31556983
Failure to thrive	20.90	15.20	16	7083	7946	31682299
Bladder disorder	20.77	15.20	11	7088	2891	31687354
Asthenia	20.56	15.20	102	6997	224653	31465592
Cerebrovascular accident	20.56	15.20	51	7048	79433	31610812
Nocturia	18.82	15.20	16	7083	9219	31681026
Faecaloma	18.37	15.20	12	7087	4644	31685601
Gait inability	18.29	15.20	22	7077	19122	31671123
Multiple sclerosis relapse	17.00	15.20	17	7082	12030	31678215
Incontinence	16.78	15.20	12	7087	5374	31684871
Hypertonic bladder	16.61	15.20	8	7091	1722	31688523
Dizziness	16.54	15.20	88	7011	199059	31491186
Blood pressure systolic increased	16.39	15.20	21	7078	19449	31670796
Rectal tenesmus	15.44	15.20	6	7093	768	31689477
Toxicity to various agents	15.33	15.20	11	7088	181476	31508769

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis	101.59	11.96	76	22905	25209	70880254
Urinary tract infection	100.84	11.96	238	22743	248531	70656932
Urinary incontinence	90.02	11.96	84	22897	37758	70867705
Sensitivity to weather change	89.36	11.96	45	22936	7360	70898103
Fall	81.15	11.96	321	22660	443775	70461688
Multiple sclerosis relapse	73.83	11.96	80	22901	42937	70862526
Pollakiuria	64.12	11.96	66	22915	33395	70872068
Bladder disorder	57.57	11.96	35	22946	8254	70897209
Dry mouth	53.66	11.96	88	22893	70369	70835094
Cerebrovascular accident	50.33	11.96	130	22851	143340	70762123
Lipoma	49.05	11.96	22	22959	2780	70902683
Hypertonic bladder	48.63	11.96	24	22957	3759	70901704
Balance disorder	42.86	11.96	92	22889	90036	70815427
Off label use	40.39	11.96	116	22865	742944	70162519
Micturition urgency	36.75	11.96	30	22951	11284	70894179
Seronegative arthritis	36.33	11.96	19	22962	3360	70902103
Urinary retention	35.22	11.96	62	22919	52458	70853005
Dizziness	33.55	11.96	261	22720	463880	70441583
Drug abuse	31.47	11.96	5	22976	147251	70758212
Prostatic specific antigen increased	30.53	11.96	25	22956	9441	70896022
Toxicity to various agents	30.46	11.96	48	22933	382124	70523339
Incontinence	29.21	11.96	28	22953	13000	70892463
Hallucination, auditory	26.18	11.96	31	22950	18297	70887166
Bladder spasm	25.96	11.96	13	22968	2100	70903363
Contraindicated product administered	25.74	11.96	6	22975	134606	70770857
Stress urinary incontinence	25.67	11.96	12	22969	1668	70903795
Maternal exposure during pregnancy	24.46	11.96	4	22977	115341	70790122
Musculoskeletal discomfort	23.58	11.96	29	22952	17803	70887660
Nocturia	23.24	11.96	24	22957	12180	70893283
Treatment failure	22.91	11.96	9	22972	144133	70761330
Febrile neutropenia	22.31	11.96	20	22961	204298	70701165
Secondary progressive multiple sclerosis	21.62	11.96	10	22971	1357	70904106
Confusional state	21.09	11.96	161	22820	284237	70621226
Paranoia	21.08	11.96	27	22954	17261	70888202
Inflammatory marker increased	20.92	11.96	20	22961	9254	70896209
Asthenia	20.74	11.96	233	22748	457433	70448030
Systemic lupus erythematosus	20.59	11.96	4	22977	101898	70803565
Gait inability	18.90	11.96	45	22936	47130	70858333
Transient ischaemic attack	18.59	11.96	44	22937	45900	70859563
Hand deformity	18.33	11.96	3	22978	86479	70818984
Drug intolerance	18.29	11.96	28	22953	225659	70679804
Drug hypersensitivity	18.03	11.96	146	22835	262313	70643150
Gastrooesophageal reflux disease	17.58	11.96	67	22914	90772	70814691
Vision blurred	17.52	11.96	69	22912	94915	70810548
Infusion related reaction	17.50	11.96	23	22958	197511	70707952
Aphonia	17.27	11.96	18	22963	9233	70896230
Body temperature fluctuation	17.27	11.96	12	22969	3547	70901916
Liver iron concentration abnormal	17.20	11.96	4	22977	58	70905405
Mental status changes	17.01	11.96	52	22929	63049	70842414
Exposure during pregnancy	16.59	11.96	4	22977	87713	70817750
Coronary artery disease	16.26	11.96	51	22930	62685	70842778
Speech disorder	14.88	11.96	43	22938	50537	70854926
Iliac artery occlusion	14.82	11.96	5	22976	294	70905169
Product complaint	14.75	11.96	19	22962	12212	70893251
Urge incontinence	14.42	11.96	7	22974	1058	70904405
Depression	14.38	11.96	112	22869	198862	70706601
Blood pressure systolic increased	14.34	11.96	46	22935	57213	70848250
Escherichia urinary tract infection	14.30	11.96	19	22962	12588	70892875
Colitis ischaemic	14.06	11.96	20	22961	14117	70891346
Neutropenia	14.01	11.96	40	22941	257116	70648347
Neutrophil count decreased	13.64	11.96	5	22976	83551	70821912
Stomatitis	13.52	11.96	13	22968	128498	70776965
Bladder adenocarcinoma stage unspecified	13.50	11.96	3	22978	35	70905428
Orthostatic hypotension	13.35	11.96	42	22939	51701	70853762
Perforation	13.28	11.96	7	22974	1258	70904205
Barrett's oesophagus	13.22	11.96	6	22975	779	70904684
Psychotic disorder	13.03	11.96	34	22947	37667	70867796
Cystitis	12.95	11.96	39	22942	46902	70858561
Wound	12.91	11.96	8	22973	98724	70806739
Dysphagia	12.71	11.96	71	22910	112763	70792700
Mixed incontinence	12.68	11.96	3	22978	47	70905416
Completed suicide	12.61	11.96	35	22946	227100	70678363
Multiple organ dysfunction syndrome	12.60	11.96	10	22971	108505	70796958
Body height decreased	12.52	11.96	14	22967	7769	70897694
Dysarthria	12.08	11.96	46	22935	62267	70843196
Hyperlipidaemia	12.08	11.96	25	22956	23838	70881625
Increased appetite	12.04	11.96	16	22965	10597	70894866
Malignant neoplasm progression	12.03	11.96	13	22968	121726	70783737
Palpitations	12.02	11.96	69	22912	110684	70794779
Urosepsis	12.02	11.96	25	22956	23924	70881539

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD07	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:53784	antispasmodics
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Torsades de pointes	contraindication	31722008
Dementia	contraindication	52448006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastrointestinal hypomotility	contraindication	421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Congenital long QT syndrome	contraindication	442917000
Aggravated Glaucoma	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.83	acidic
pKa2	9.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.49	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.57	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.51	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.66	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	7.77	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.16	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8.15	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR		ACM5_RAT		Ki	8.66	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR		ACM4_RAT		Ki	8.51	CHEMBL

External reference:

ID	Source
4024113	VUID
N0000022118	NUI
D00646	KEGG_DRUG
124937-52-6	SECONDARY_CAS_RN
4021103	VANDF
4024113	VANDF
C0388753	UMLSCUI
CHEBI:9622	CHEBI
CHEMBL1382	ChEMBL_ID
DB01036	DRUGBANK_ID
CHEMBL1722209	ChEMBL_ID
D000068737	MESH_DESCRIPTOR_UI
443879	PUBCHEM_CID
360	IUPHAR_LIGAND_ID
6768	INN_ID
WHE7A56U7K	UNII
119565	RXNORM
191519	MMSL
5600	MMSL
d04294	MMSL
007444	NDDF
007445	NDDF
109113000	SNOMEDCT_US
372570008	SNOMEDCT_US
386971005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4541	TABLET, FILM COATED	1 mg	ORAL	NDA	25 sections
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4544	TABLET, FILM COATED	2 mg	ORAL	NDA	25 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5190	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	NDA	29 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5191	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	NDA	29 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0010	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0010	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0018	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0018	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6592	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6593	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	20 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-706	TABLET, EXTENDED RELEASE	1 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-706	TABLET, EXTENDED RELEASE	1 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-707	TABLET, EXTENDED RELEASE	2 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-707	TABLET, EXTENDED RELEASE	2 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	16571-126	TABLET, FILM COATED	1 mg	ORAL	ANDA	21 sections
Tolterodine Tartrate	Human Prescription Drug Label	1	16571-127	TABLET, FILM COATED	2 mg	ORAL	ANDA	21 sections
DETROL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-959	TABLET, FILM COATED	2 mg	ORAL	NDA	23 sections
Tolterodine tartrate	Human Prescription Drug Label	1	27241-191	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine tartrate	Human Prescription Drug Label	1	27241-192	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-239	TABLET	1 mg	ORAL	ANDA	20 sections